Effect of setmelanotide, a melanocortin‐4 receptor agonist, on obesity in Bardet‐Biedl syndrome

AIM: To report an analysis of ~1 year of setmelanotide treatment for obesity and hunger, as well as metabolic and cardiac outcomes, in individuals with Bardet‐Biedl syndrome (BBS). MATERIALS AND METHODS: Individuals aged 12 years and older with BBS received once‐daily setmelanotide. The dose was tit...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetes Obes Metab
Autors principals: Haws, Robert, Brady, Sheila, Davis, Elisabeth, Fletty, Kristina, Yuan, Guojun, Gordon, Gregory, Stewart, Murray, Yanovski, Jack
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Publishing Ltd 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7689750/
https://ncbi.nlm.nih.gov/pubmed/32627316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14133
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars